Zydus Cadila acquires 100% stake in Mumbai-based Biochem

21 Dec 2011 Evaluate

Zydus Cadila has acquired 100% stake in Mumbai-based Biochem, one of the top 40 pharma companies in India. This acquisition strengthens the company’s operations in the Indian pharma market.

Zydus Cadila has been on the hunt for companies that are small in size and have specific product pipelines. Zydus Cadila is looking at every strategic opportunity to grow and contribute to Indian market, either by way of novel initiatives, collaborations or acquisitions.

Biochem is a well-integrated pharma player with a presence in the antibiotics, cardiovascular, anti-diabetic and oncological segments. For the year 2010-2011, Biochem has reported sales of Rs 264.5 crore.

Biochem has proven strengths in manufacturing and marketing of antibiotics. The top 5 brands of the company are Ampilox, Biotax, Monotax, Amicin and Zithrocin which together contribute to 40% of the company's sales. Three of Biochem's brands fall in the top 300 pharma brands of India.

Cadila Pharmaceuticals is part of the Zydus Cadila Group, focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.

Zydus Lifesciences Share Price

993.40 10.35 (1.05%)
13-May-2024 15:30 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1530.00
Dr. Reddys Lab 5913.95
Cipla 1421.00
Zydus Lifesciences 993.40
Lupin 1684.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.